Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union
- Details
- Category: Sanofi
Sanofi and GSK finalized and signed today an Advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine, once the vaccine is approved. The vaccine candidate is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established adjuvant technology.
Lilly and Amgen announce manufacturing collaboration for COVID-19 antibody therapies
- Details
- Category: Amgen
Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies. Lilly is currently studying several potential neutralizing antibodies for the prevention and/or treatment of COVID-19 as either monotherapy or in combination.
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
- Details
- Category: AstraZeneca
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators. The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume.
CureVac expected to receive up to 252 million euros from the German Federal Ministry of Research for further COVID-19 vaccine development and production capacity expansion
- Details
- Category: Business
CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials, has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to 252 million euros to support the development of its COVID-19 vaccine candidate.
Sinovac reports preliminary Phase I/II results of COVID-19 vaccine in elderly volunteers
- Details
- Category: Business
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccine candidate developed by Sinovac Life Sciences (Sinovac LS), or "CoronaVac," shows good safety and immunogenicity on healthy adults aged 60 and above from its phase I/II clinical studies conducted in China, which is comparable to the result in healthy adults aged from 18 to 59 in the earlier studies.
Pfizer and BioNTech announce data from preclinical studies of mRNA-based vaccine candidate against COVID-19
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against SARS-CoV-2, the virus that causes COVID-19 disease. In a non-human primate preclinical study, immunization with the BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate, protected rhesus macaques against SARS-CoV-2 infection.
More Pharma News ...
- Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause
- Biopharma leaders unite to stand with science
- Johnson & Johnson announces that Janssen's COVID-19 investigational vaccine candidate prevents severe clinical disease in pre-clinical studies
- Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidate
- New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
- Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
- Sanofi provides update on Kevzara® (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.